Waregem (Belgium) / Rotterdam (The Netherlands)[1], 11 April 2014 – Arseus announced today that it has reached agreement on the pricing of the successful US Private Placement (US PP) of US$ 185 million. The US PP was initially offered for US$ 100 million, but was oversubscribed by US$ 85 million because of strong demand. The US PP is in line with Arseus’ financial strategy to further diversify its sources of financing.
The US PP consists of several tranches with maturities of 3, 5 and 7 years in both US dollars and euros. The average annual fixed interest rate is 4.6%.
The transaction is expected to be closed on 15 April 2014. The funds of the US PP, will be used to partly repay existing loans and to finance acquisitions.
ING Financial Markets LLC acted as Sole Placement Agent and Joint Bookrunner in this transaction and Commerzbank as Joint Bookrunner.
For further information:
Marieke Palstra
Director Investor Relations
+ 31 88 33 11 213 (office)
marieke.palstra@arseus.com
Arseus profile
Arseus is a scientific R&D company that supplies innovative solutions and concepts to professionals and institutions in the healthcare sector in 30 countries around the world. Arseus is made up of three divisions: Fagron is the global market leader in pharmaceutical compounding. Corilus develops and supplies medical specialists with unique integrated ICT solutions with substantial added value. Corilus is the market leader in selected segments in Belgium, France and the Netherlands. HL Technology develops and produces innovative precision components and orthopaedic tools for dental and medical professionals. The Belgian company Arseus NV is located in Waregem and is listed on NYSE Euronext Brussels and NYSE Euronext Amsterdam. The operational activities of the Arseus group are driven by the Dutch company Arseus BV. The head office of Arseus BV is located in Rotterdam.
[1] This press release was sent out by Arseus NV and Arseus BV.
Please open the link below for the press release: